Leafy Tunnel

Leafy Tunnel invests in early-stage companies developing pharmaceutical-grade cannabinoids and psychedelic compounds for treatment-resistant mental-health conditions. The firm targets indications such as PTSD, depression, and chronic pain where existing treatments have high failure rates. Its thesis relies on regulatory liberalization in Europe and North America creating new addressable markets for clinically validated alternative therapies.

Leafy Tunnel's disclosed portfolio centers on biopharmaceutical companies pursuing clinical-trial pathways and drug-development intellectual property, rather than retail, cultivation, or consumer-packaged-goods cannabis. The firm's known holding, Oxford Cannabinoid Technologies, is a prescription-drug developer, suggesting a focus on regulated pharmaceutical applications over commercial or adult-use markets.

The firm focuses on seed and Series A rounds, entering at the earliest stages of company formation when regulatory-risk premiums are highest. This early-stage posture differentiates it from later-stage healthcare funds that prefer de-risked assets closer to commercial launch.

Leafy Tunnel deploys capital in Europe and North America. Its known portfolio includes UK-domiciled Oxford Cannabinoid Technologies, and the firm has indicated additional European exposure in the psychedelic-research segment. The dual-continent strategy gives it access to both the European Medicines Agency and FDA regulatory pathways.

Leafy Tunnel operates as a specialized early-stage private-equity manager without publicly disclosed fund structures, co-investment vehicles, or parallel foundations. The firm maintains a lean operating model consistent with a concentrated sector mandate, but detailed fund terms and vehicle architecture have not been made public.